Conmed expands portfolio with Bard's endoscopic line
This article was originally published in Clinica
Conmed is to acquire from CR Bard certain products from its Endoscopic Technologies business, including its line of single-use medical devices used to diagnose and treat diseases of the digestive tract and lungs. The transaction will cost Conmed $80m in total, of which $30m will be an up-front cash payment and the rest in borrowings under its revolving line of credit.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.